Innovative coeliac strategy shows promise

French researchers have demonstrated that a naturally produced anti-inflammatory protein is less abundant in coeliac patients compared with healthy people, opening the way to new possible therapies for the disease.

Expression of the human serine protease inhibitor elafin in the small intestinal epithelium was lower in patients with active coeliac disease, the authors from the French Institute for Health and Medical Research found.

In vitro experiments revealed that elafin could prevent the destruction of the